False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam--is it still an issue?
We evaluated the impact of piperacillin/tazobactam (PT) therapy on galactomannan enzyme immunoassay (GEI) testing (Platelia; Bio-Rad, Marnes La Coquette, France). Galactomannan contents of PT batches were highly variable. We found that false-positive GEI results can be avoided by performance of blood sampling before PT administration and by using separate sites for blood sampling and for administration of antibiotics.
Penack
Olaf
O
Hematology and Oncology, Campus Benjamin Franklin, D-12200 Berlin, Germany. penacko@mskcc.org
Rempf
Patricia
P
Graf
Barbara
B
Thiel
Eckhard
E
Blau
Igor Wolfgang
IW
D000328:Adult; D000946:Antigens, Fungal / Q000097:blood*; D001228:Aspergillosis / Q000175:diagnosis*; D005189:False Positive Reactions; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods; D008351:Mannans / Q000097:blood*; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use*; D000078142:Tazobactam
D000946:Antigens, Fungal; D008351:Mannans; C012990:galactomannan; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin; D005690:Galactose